Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX and ISIN Numbers 29 Article 3. Covenants 29 Section 3.01. Payment on Notes 29 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 Section 3.06. Stay, Extension and Usury Laws 31 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 Article 4. Repurchase and Redemption 32 Section 4.01. No Sinking Fund 32 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon a Fundamental Change 32 Section 4.03. Right of the Company to Redeem the Notes 36 Article 5. Conversion 39 Section 5.01. Right to Convert 39 Section 5.02. Conversion Procedures 43 Section 5.03. Settlement Upon Conversion 45 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 Section 5.05. Adjustments to the Conversion Rate 49 Section 5.06. Voluntary Adjustments 60 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 Section 5.08. Exchange in Lieu of Conversion 62 Section 5.09. Effect of Common Stock Change Event 63 Article 6. Successors 65 Section 6.01. When the Company May Merge, Etc. 65 Section 6.02. Successor Entity Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 Article 7. Defaults and Remedies 66 Section 7.01. Events of Default 66 Section 7.02. Acceleration 68 Section 7.03. Sole Remedy for a Failure to Report 68 Section 7.04. Other Remedies 70 Section 7.05. Waiver of Past Defaults 70 Section 7.06. Control by Majority 70 Section 7.07. Limitation on Suits 70 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 Section 7.09. Collection Suit by Trustee 71 Section 7.10. Trustee May File Proofs of Claim 71 Section 7.11. Priorities 72 Section 7.12. Undertaking for Costs 72 Article 8. Amendments, Supplements and Waivers 73 Section 8.01. Without the Consent of Holders 73 Section 8.02. With the Consent of Holders 74 Section 8.03. Notice of Amendments, Supplements and Waivers 75 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 Section 8.05. Notations and Exchanges 76 Section 8.06. Trustee to Execute Supplemental Indentures 76 Article 9. Satisfaction and Discharge 76 Section 9.01. Termination of Company’s Obligations 76 Section 9.02. Repayment to Company 77 Section 9.03. Reinstatement 77 Article 10. Trustee 77 Section 10.01. Duties of the Trustee 77 Section 10.02. Rights of the Trustee 79 Section 10.03. Individual Rights of the Trustee 80 Section 10.04. Trustee’s Disclaimer 80 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 Section 10.07. Replacement of the Trustee 81 Section 10.08. Successor Trustee by Xxxxxx, Etc. 82 Section 10.09. Eligibility; Disqualification 83 Article 11. Miscellaneous 83 Section 11.01. Notices 83 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 Section 11.04. Rules by the Trustee, the Registrar, the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 18 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 19 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 25 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 26 Section 2.16. Notes Held by the Company or its Affiliates 27 26 Section 2.17. Temporary Notes 27 26 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 27 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 28 Section 3.03. Rule 144A Information 30 28 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 30 Section 3.06. Stay, Extension and Usury Laws 31 30 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 30 Article 4. Repurchase and Redemption 32 30 Section 4.01. No Sinking Fund 32 30 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 30 Section 4.03. Right of the Company to Redeem the Notes 36 35 Article 5. Conversion 39 38 Section 5.01. Right to Convert 39 Convert. 38 Section 5.02. Conversion Procedures 43 42 Section 5.03. Settlement Upon upon Conversion 45 43 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 46 Section 5.05. Adjustments to the Conversion Rate 49 47 Section 5.06. Voluntary Adjustments 60 57 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 57 Section 5.08. Exchange in Lieu of Conversion 62 59 Section 5.09. Effect of Common Stock Change Event 63 59 Article 6. Successors 65 61 Section 6.01. When the Company May Merge, Etc. 65 61 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 62 Article 7. Defaults and Remedies 66 62 Section 7.01. Events of Default 66 62 Section 7.02. Acceleration 68 64 Section 7.03. Sole Remedy for a Failure to Report 68 65 Section 7.04. Other Remedies 70 66 Section 7.05. Waiver of Past Defaults 70 66 Section 7.06. Control by Majority 70 66 Section 7.07. Limitation on Suits 70 66 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 67 Section 7.09. Collection Suit by Trustee 71 67 Section 7.10. Trustee May File Proofs of Claim 71 67 Section 7.11. Priorities 72 68 Section 7.12. Undertaking for Costs 72 68 Article 8. Amendments, Supplements and Waivers 73 69 Section 8.01. Without the Consent of Holders 73 69 Section 8.02. With the Consent of Holders 74 70 Section 8.03. Notice of Amendments, Supplements and Waivers 75 71 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 71 Section 8.05. Notations and Exchanges 76 72 Section 8.06. Trustee to Execute Supplemental Indentures 76 72 Article 9. Guarantees 72 Section 9.01. Guarantees 72 Section 9.02. Limitation on Guarantor Liability 73 Section 9.03. Execution and Delivery of Guarantee 74 Section 9.04. When Guarantors May Merge, Etc. 74 Section 9.05. Future Guarantors 74 Section 9.06. Application of Certain Provisions to the Guarantors 75 Section 9.07. Release of Guarantors 75 Article 10. Satisfaction and Discharge 76 75 Section 9.0110.01. Termination of Company’s Obligations 76 75 Section 9.0210.02. Repayment to Company 77 76 Section 9.0310.03. Reinstatement 77 76 Article 1011. Trustee 77 Section 10.0111.01. Duties of the Trustee 77 Section 10.0211.02. Rights of the Trustee 78 Section 11.03. Individual Rights of the Trustee 79 Section 10.0311.04. Individual Rights Trustee’s Disclaimer 79 Section 11.05. Notice of Defaults 79 Section 11.06. Compensation and Indemnity 79 Section 11.07. Replacement of the Trustee 80 Section 10.04. Trustee’s Disclaimer 80 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 Section 10.07. Replacement of the Trustee 81 Section 10.0811.08. Successor Trustee by XxxxxxMerger, Etc. 82 81 Section 10.0911.09. Eligibility; Disqualification 83 81 Article 1112. Miscellaneous 83 81 Section 11.0112.01. Notices 83 81 Section 11.0212.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 83 Section 11.0312.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 83 Section 11.0412.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 84 Section 11.0512.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 84 Section 11.0612.06. Governing Law; Waiver of Jury Trial 86 84 Section 11.0712.07. Submission to Jurisdiction 86 84 Section 11.0812.08. No Adverse Interpretation of Other Agreements 86 85 Section 11.0912.09. Successors 86 85 Section 11.1012.10. Force Majeure 87 85 Section 11.1112.11. U.S.A. PATRIOT Act 87 85 Section 11.1212.12. Calculations 87 85 Section 11.1312.13. Severability 87 86 Section 11.1412.14. Counterparts 87 86 Section 11.1512.15. Table of Contents, Headings, Etc. 88 86 Section 11.1612.16. Withholding Taxes 88 86 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17May 1, 20232020, between Mirum Pharmaceuticals, Inc.among CNX Resources Corporation, a Delaware corporation, as issuer (the “Company”), the Guarantors (as defined herein) party hereto and U.S. Bank Trust CompanyUMB Bank, National AssociationN.A., as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.002.25% Convertible Senior Notes due 2029 2026 (the “Notes”).
Appears in 1 contract
Samples: Indenture (CNX Resources Corp)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 14 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 15 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 16 Section 2.08. Holder Lists 19 16 Section 2.09. Legends 19 16 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 17 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 22 Section 2.12. Removal of Transfer Restrictions 26 23 Section 2.13. Replacement Notes 26 23 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 23 Section 2.15. Cancellation 27 24 Section 2.16. Notes Held by the Company or its Affiliates 27 24 Section 2.17. Temporary Notes 27 24 Section 2.18. Outstanding Notes 28 24 Section 2.19. Repurchases by the Company 28 25 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 25 Article 3. Covenants 29 25 Section 3.01. Payment on Notes 29 25 Section 3.02. Exchange Act Reports 29 26 Section 3.03. Rule 144A Information 30 26 Section 3.04. Additional Interest 30 26 Section 3.05. Compliance and Default Certificates 31 27 Section 3.06. Stay, Extension and Usury Laws 31 28 Section 3.07. Corporate Existence 28 Section 3.08. Restriction on Acquisition of Notes by the Company and its Affiliates 32 28 Section 3.09. Further Instruments and Acts 28 Article 4. Repurchase and Redemption 32 Xxxxxxxxxx 00 Section 4.01. No Sinking Fund 32 29 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 29 Section 4.03. No Right of Redemption by the Company to Redeem the Notes 36 33 Article 5. Conversion 39 33 Section 5.01. Right to Convert 39 33 Section 5.02. Conversion Procedures 43 36 Section 5.03. Settlement Upon upon Conversion 45 38 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 41 Section 5.05. Adjustments to the Conversion Rate 49 41 Section 5.06. Voluntary Adjustments 60 52 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 52 Section 5.08. Exchange in Lieu of Conversion 62 Section 5.09. Effect of Common Stock Change Event 63 53 Article 6. Successors 65 55 Section 6.01. When the Company May Merge, Etc. 65 55 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 55 Article 7. Defaults and Remedies 66 56 Section 7.01. Events of Default 66 56 Section 7.02. Acceleration 68 58 Section 7.03. Sole Remedy for a Failure to Report 68 58 Section 7.04. Other Remedies 70 59 Section 7.05. Waiver of Past Defaults 70 59 Section 7.06. Control by Majority 70 60 Section 7.07. Limitation on Suits 70 60 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 61 Section 7.09. Collection Suit by Trustee 71 61 Section 7.10. Trustee May File Proofs of Claim 71 61 Section 7.11. Priorities 72 62 Section 7.12. Undertaking for Costs 72 62 Article 8. Amendments, Supplements and Waivers 73 62 Section 8.01. Without the Consent of Holders 73 62 Section 8.02. With the Consent of Holders 74 63 Section 8.03. Notice of Amendments, Supplements and Waivers 75 64 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 64 Section 8.05. Notations and Exchanges 76 65 Section 8.06. Trustee to Execute Supplemental Indentures 76 65 Article 9. Satisfaction and Discharge 76 66 Section 9.01. Termination of Company’s Obligations 76 66 Section 9.02. Repayment to Company 77 66 Section 9.03. Reinstatement 77 67 Article 10. Trustee 77 67 Section 10.01. Duties of the Trustee 77 67 Section 10.02. Rights of the Trustee 79 68 Section 10.03. Individual Rights of the Trustee 80 68 Section 10.04. Trustee’s Disclaimer 80 69 Section 10.05. Notice of Defaults 80 69 Section 10.06. Compensation and Indemnity 81 69 Section 10.07. Replacement of the Trustee 81 70 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 71 Section 10.09. Eligibility; Disqualification 83 71 Section 10.10. Reports by Trustee 71 Article 11. Miscellaneous 83 71 Section 11.01. Notices 83 71 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 73 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 73 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 73 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 73 Section 11.06. Governing Law; Waiver of Jury Trial 86 74 Section 11.07. Submission to Jurisdiction 86 74 Section 11.08. No Adverse Interpretation of Other Agreements 86 74 Section 11.09. Successors 86 74 Section 11.10. Force Majeure 87 74 Section 11.11. U.S.A. PATRIOT Patriot Act 87 75 Section 11.12. Calculations 87 75 Section 11.13. Severability 87 75 Section 11.14. Counterparts 87 75 Section 11.15. Table of Contents, Headings, Etc. 88 75 Section 11.16. Withholding Taxes 88 75 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 D-1 INDENTURE, dated as of April 17September 29, 20232017, between Mirum PharmaceuticalsAir Transport Services Group, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.001.125% Convertible Senior Notes due 2029 2024 (the “Notes”).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 19 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 Section 3.01. Payment on Notes 29 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 Section 3.06. Stay, Extension and Usury Laws 31 Section 3.07. Restriction on Acquisition of Notes by the Company and its Affiliates 32 31 Article 4. Repurchase and Redemption 32 31 Section 4.01. No Sinking Fund 32 31 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 Section 4.03. Right of the Company to Redeem the Notes 36 Article 5. Conversion 39 Section 5.01. Right to Convert 39 Section 5.02. Conversion Procedures 43 Section 5.03. Settlement Upon upon Conversion 45 Section 5.04. Reserve and Status of Class A Common Stock Issued Upon upon Conversion 49 48 Section 5.05. Adjustments to the Conversion Rate 49 Section 5.06. Voluntary Adjustments 60 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 60 Section 5.08. Exchange in Lieu of Conversion 62 61 Section 5.09. Effect of Common Stock Change Event 63 62 Article 6. Successors 65 64 Section 6.01. When the Company May Merge, Etc. 65 64 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 Article 7. Defaults and Remedies 66 65 Section 7.01. Events of Default 66 65 Section 7.02. Acceleration 68 67 Section 7.03. Sole Remedy for a Failure to Report 68 67 Section 7.04. Other Remedies 70 68 Section 7.05. Waiver of Past Defaults 70 69 Section 7.06. Control by Majority 70 69 Section 7.07. Limitation on Suits 70 69 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 70 Section 7.09. Collection Suit by Trustee 71 70 Section 7.10. Trustee May File Proofs of Claim 71 70 Section 7.11. Priorities 72 71 Section 7.12. Undertaking for Costs 72 71 Article 8. Amendments, Supplements and Waivers 73 72 Section 8.01. Without the Consent of Holders 73 72 Section 8.02. With the Consent of Holders 74 73 Section 8.03. Notice of Amendments, Supplements and Waivers 75 74 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 Etc 74 Section 8.05. Notations and Exchanges 76 75 Section 8.06. Trustee to Execute Supplemental Indentures 76 75 Article 9. Satisfaction and Discharge 76 75 Section 9.01. Termination of Company’s Obligations 76 75 Section 9.02. Repayment to Company 77 76 Section 9.03. Reinstatement 77 76 Article 10. Trustee 77 76 Section 10.01. Duties of the Trustee 77 76 Section 10.02. Rights of the Trustee 79 78 Section 10.03. Individual Rights of the Trustee 80 79 Section 10.04. Trustee’s Disclaimer 80 Disclaimer. 79 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 80 Section 10.07. Replacement of the Trustee 81 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 Section 10.09. Eligibility; Disqualification 83 82 Article 11. Miscellaneous 83 82 Section 11.01. Notices 83 82 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 83 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 84 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 84 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 84 Section 11.06. Governing Law; Waiver of Jury Trial 86 84 Section 11.07. Submission to Jurisdiction 86 85 Section 11.08. No Adverse Interpretation of Other Agreements 86 85 Section 11.09. Successors 86 85 Section 11.10. Force Majeure 87 85 Section 11.11. U.S.A. PATRIOT Act 87 85 Section 11.12. Calculations 87 86 Section 11.13. Severability 87 86 Section 11.14. Counterparts 87 86 Section 11.15. Table of Contents, Headings, Etc. 88 86 Section 11.16. Withholding Taxes 88 87 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17August 11, 20232020, between Mirum Pharmaceuticals, Inc.Bloom Energy Corporation, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.002.50% Green Convertible Senior Notes due 2029 2025 (the “Notes”).
Appears in 1 contract
Samples: Indenture (Bloom Energy Corp)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 30 Section 3.06. Stay, Extension and Usury Laws 31 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 31 Article 4. Repurchase and Redemption 32 31 Section 4.01. No Sinking Fund 32 31 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon a Fundamental Change 32 31 Section 4.03. Right of the Company to Redeem the Notes 36 Article 5. Conversion 39 Section 5.01. Right to Convert 39 Section 5.02. Conversion Procedures 43 Section 5.03. Settlement Upon Conversion 45 44 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 48 Section 5.05. Adjustments to the Conversion Rate 49 Section 5.06. Voluntary Adjustments 60 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 60 Section 5.08. Exchange in Lieu of Conversion 62 61 Section 5.09. Effect of Common Stock Change Event 63 62 Article 6. Successors 65 64 Section 6.01. When the Company May Merge, Etc. 65 64 Section 6.02. Successor Entity Substituted 65 64 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 Article 7. Defaults and Remedies 66 65 Section 7.01. Events of Default 66 65 Section 7.02. Acceleration 68 67 Section 7.03. Sole Remedy for a Failure to Report 68 67 Section 7.04. Other Remedies 70 68 Section 7.05. Waiver of Past Defaults 70 69 Section 7.06. Control by Majority 70 69 Section 7.07. Limitation on Suits 70 69 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 70 Section 7.09. Collection Suit by Trustee 71 70 Section 7.10. Trustee May File Proofs of Claim 71 70 Section 7.11. Priorities 72 71 Section 7.12. Undertaking for Costs 72 71 Article 8. Amendments, Supplements and Waivers 73 71 Section 8.01. Without the Consent of Holders 73 71 Section 8.02. With the Consent of Holders 74 72 Section 8.03. Notice of Amendments, Supplements and Waivers 75 73 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 74 Section 8.05. Notations and Exchanges 76 74 Section 8.06. Trustee to Execute Supplemental Indentures 76 75 Article 9. Satisfaction and Discharge 76 75 Section 9.01. Termination of Company’s Obligations 76 75 Section 9.02. Repayment to Company 77 76 Section 9.03. Reinstatement 77 76 Article 10. Trustee 77 76 Section 10.01. Duties of the Trustee 77 76 Section 10.02. Rights of the Trustee 79 77 Section 10.03. Individual Rights of the Trustee 80 78 Section 10.04. Trustee’s Disclaimer 80 78 Section 10.05. Notice of Defaults 80 79 Section 10.06. Compensation and Indemnity 81 79 Section 10.07. Replacement of the Trustee 81 80 Section 10.08. Successor Trustee by Xxxxxx, Etc. 82 81 Section 10.09. Eligibility; Disqualification 83 81 Article 11. Miscellaneous 83 81 Section 11.01. Notices 83 Notices. 81 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 83 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 83 Section 11.04. Rules by the Trustee, the Registrar, the Paying Agent and the Conversion Agent 85 84 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 84 Section 11.06. Governing Law; Waiver of Jury Trial 86 84 Section 11.07. Submission to Jurisdiction 86 84 Section 11.08. No Adverse Interpretation of Other Agreements 86 85 Section 11.09. Successors 86 85 Section 11.10. Force Majeure 87 85 Section 11.11. U.S.A. PATRIOT Act 87 85 Section 11.12. Calculations 87 85 Section 11.13. Severability 87 86 Section 11.14. Counterparts 87 86 Section 11.15. Table of Contents, Headings, Etc. 88 86 Section 11.16. Withholding Taxes 88 86 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17March 10, 2023, between Mirum PharmaceuticalsRivian Automotive, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.004.625% Green Convertible Senior Notes due 2029 (the “Notes”).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 15 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 15 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 16 Section 2.08. Holder Lists 19 16 Section 2.09. Legends 19 17 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 18 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 22 Section 2.12. Removal of Transfer Restrictions 26 23 Section 2.13. Replacement Notes 26 23 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 24 Section 2.15. Cancellation 27 24 Section 2.16. Notes Held by the Company or its Affiliates 27 24 Section 2.17. Temporary Notes 27 24 Section 2.18. Outstanding Notes 28 25 Section 2.19. Repurchases by the Company 28 25 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 26 Article 3. Covenants 29 26 Section 3.01. Payment on Notes 29 26 Section 3.02. Exchange Act Reports 29 26 Section 3.03. Rule 144A Information 30 27 Section 3.04. Additional Interest 30 27 Section 3.05. Compliance and Default Certificates 31 28 Section 3.06. Stay, Extension and Usury Laws 31 28 Section 3.07. Corporate Existence 29 Section 3.08. Restriction on Acquisition of Notes by the Company and its Affiliates 32 29 Section 3.09. Further Instruments and Acts 29 Article 4. Repurchase and Redemption 32 Xxxxxxxxxx 00 Section 4.01. No Sinking Fund 32 29 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 29 Section 4.03. No Right of Redemption by the Company to Redeem the Notes 36 33 Article 5. Conversion 39 33 Section 5.01. Right to Convert 39 33 Section 5.02. Conversion Procedures 43 36 Section 5.03. Settlement Upon upon Conversion 45 38 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 40 Section 5.05. Adjustments to the Conversion Rate 49 41 Section 5.06. Voluntary Adjustments 60 51 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 52 Section 5.08. Exchange in Lieu of Conversion 62 Section 5.09. Effect of Common Stock Change Event 63 53 Article 6. Successors 65 54 Section 6.01. When the Company May Merge, Etc. 65 54 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 55 Article 7. Defaults and Remedies 66 55 Section 7.01. Events of Default 66 55 Section 7.02. Acceleration 68 57 Section 7.03. Sole Remedy for a Failure to Report 68 58 Section 7.04. Other Remedies 70 59 Section 7.05. Waiver of Past Defaults 70 59 Section 7.06. Control by Majority 70 59 Section 7.07. Limitation on Suits 70 59 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 60 Section 7.09. Collection Suit by Trustee 71 60 Section 7.10. Trustee May File Proofs of Claim 71 60 Section 7.11. Priorities 72 61 Section 7.12. Undertaking for Costs 72 61 Article 8. Amendments, Supplements and Waivers 73 62 Section 8.01. Without the Consent of Holders 73 62 Section 8.02. With the Consent of Holders 74 63 Section 8.03. Notice of Amendments, Supplements and Waivers 75 64 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 64 Section 8.05. Notations and Exchanges 76 64 Section 8.06. Trustee to Execute Supplemental Indentures 76 65 Article 9. Satisfaction and Discharge 76 65 Section 9.01. Termination of Company’s Obligations 76 65 Section 9.02. Repayment to Company 77 66 Section 9.03. Reinstatement 77 66 Article 10. Trustee 77 66 Section 10.01. Duties of the Trustee 77 66 Section 10.02. Rights of the Trustee 79 67 Section 10.03. Individual Rights of the Trustee 80 68 Section 10.04. Trustee’s Disclaimer 80 68 Section 10.05. Notice of Defaults 80 68 Section 10.06. Compensation and Indemnity 81 68 Section 10.07. Replacement of the Trustee 81 69 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 70 Section 10.09. Eligibility; Disqualification 83 70 Article 11. Miscellaneous 83 70 Section 11.01. Notices 83 70 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 72 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 72 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 73 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 73 Section 11.06. Governing Law; Waiver of Jury Trial 86 73 Section 11.07. Submission to Jurisdiction 86 73 Section 11.08. No Adverse Interpretation of Other Agreements 86 73 Section 11.09. Successors 86 74 Section 11.10. Force Majeure 87 74 Section 11.11. U.S.A. PATRIOT Act 87 74 Section 11.12. Calculations 87 74 Section 11.13. Severability 87 74 Section 11.14. Counterparts 87 74 Section 11.15. Table of Contents, Headings, Etc. 88 75 Section 11.16. Withholding Taxes 88 75 Section 11.17. Benefits of Indenture 75 Section 11.18. No Security Interest Created 75 Exhibits Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 1726, 20232019, between Mirum PharmaceuticalsGuess?, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.002.00% Convertible Senior Notes due 2029 2024 (the “Notes”).
Appears in 1 contract
Samples: Indenture (Guess Inc)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 19 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 21 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 26 Section 2.12. Removal of Transfer Restrictions 26 27 Section 2.13. Replacement Notes 26 27 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 Section 2.15. Cancellation 27 28 Section 2.16. Notes Held by the Company or its Affiliates 27 28 Section 2.17. Temporary Notes 27 28 Section 2.18. Outstanding Notes 28 Section 2.19. Repurchases by the Company 28 29 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 Article 3. Covenants 29 30 Section 3.01. Payment on Notes 29 30 Section 3.02. Exchange Act Reports 29 30 Section 3.03. Rule 144A Information 30 31 Section 3.04. Additional Interest 30 31 Section 3.05. Compliance and Default Certificates 31 32 Section 3.06. Stay, Extension and Usury Laws 31 32 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 Corporate Existence 33 Article 4. Repurchase and Redemption 32 33 Section 4.01. No Sinking Fund 32 33 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 33 Section 4.03. Right of the Company to Redeem the Notes 36 37 Article 5. Conversion 39 41 Section 5.01. Right to Convert 39 41 Section 5.02. Conversion Procedures 43 44 Section 5.03. Settlement Upon upon Conversion 45 46 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 50 Section 5.05. Adjustments to the Conversion Rate 49 50 Section 5.06. Voluntary Adjustments 60 61 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 62 Section 5.08. Exchange in Lieu of Conversion 62 63 Section 5.09. Effect of Common Stock Change Event 63 64 Article 6. Successors 65 Section 6.01. When the Company May Merge, Etc. 65 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 66 Article 7. Defaults and Remedies 66 Section 7.01. Events of Default 66 Section 7.02. Acceleration 68 Section 7.03. Sole Remedy for a Failure to Report 68 69 Section 7.04. Other Remedies 70 Section 7.05. Waiver of Past Defaults 70 Section 7.06. Control by Majority 70 71 Section 7.07. Limitation on Suits 70 71 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 Section 7.09. Collection Suit by Trustee 71 72 Section 7.10. Trustee May File Proofs of Claim 71 72 Section 7.11. Priorities 72 Section 7.12. Undertaking for Costs 72 73 Article 8. Amendments, Supplements and Waivers 73 Section 8.01. Without the Consent of Holders 73 Section 8.02. With the Consent of Holders 74 Section 8.03. Notice of Amendments, Supplements and Waivers 75 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 Section 8.05. Notations and Exchanges 76 Section 8.06. Trustee to Execute Supplemental Indentures 76 Article 9. Satisfaction and Discharge 76 77 Section 9.01. Termination of Company’s Obligations 76 77 Section 9.02. Repayment to Company 77 Section 9.03. Reinstatement 77 78 Article 10. Trustee 77 78 Section 10.01. Duties of the Trustee 77 78 Section 10.02. Rights of the Trustee 79 Section 10.03. Individual Rights of the Trustee 80 81 Section 10.04. Trustee’s Disclaimer 80 81 Section 10.05. Notice of Defaults 80 82 Section 10.06. Compensation and Indemnity 81 82 Section 10.07. Replacement of the Trustee 81 83 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 84 Section 10.09. Eligibility; Disqualification 83 84 Article 11. Miscellaneous 83 84 Section 11.01. Notices 83 84 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 86 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 87 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 87 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 87 Section 11.06. Governing Law; Waiver of Jury Trial 86 87 Section 11.07. Submission to Jurisdiction 86 88 Section 11.08. No Adverse Interpretation of Other Agreements 86 88 Section 11.09. Successors 86 88 Section 11.10. Force Majeure 87 88 Section 11.11. U.S.A. PATRIOT Act 87 88 Section 11.12. Calculations 87 89 Section 11.13. Severability 87 89 Section 11.14. Counterparts 87 89 Section 11.15. Table of Contents, Headings, Etc. 88 89 Section 11.16. Withholding Taxes 88 89 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 Exhibit B-4: Form of Canadian Restricted Securities Legend B4-1 INDENTURE, dated as of April 17March 5, 20232021, between Mirum Pharmaceuticals, Ceridian HCM Holding Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust CompanyXxxxx Fargo Bank, National Association, not in its individual capacity but solely as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.000.25% Convertible Senior Notes due 2029 2026 (the “Notes”).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 18 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 19 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 25 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 26 Section 2.16. Notes Held by the Company or its Affiliates 27 26 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX and ISIN CUSIP Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 28 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 30 Section 3.06. Stay, Extension and Usury Laws 31 30 Section 3.07. Corporate Existence 31 Section 3.08. Restriction on Acquisition of Notes by the Company and its Affiliates 32 31 Article 4. Repurchase and Redemption 32 31 Section 4.01. No Sinking Fund 32 31 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 31 Section 4.03. Right of the Company to Redeem the Notes 36 Article 5. Conversion 39 38 Section 5.01. Right to Convert 39 38 Section 5.02. Conversion Procedures 43 42 Section 5.03. Settlement Upon upon Conversion 45 44 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 47 Section 5.05. Adjustments to the Conversion Rate 49 47 Section 5.06. Voluntary Adjustments 60 58 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 58 Section 5.08. Exchange in Lieu of Conversion 62 60 Section 5.09. Effect of Common Stock Change Event 63 60 Article 6. Successors 65 62 Section 6.01. When the Company May Merge, Etc. 65 Etc 62 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 63 Article 7. Defaults and Remedies 66 63 Section 7.01. Events of Default 66 63 Section 7.02. Acceleration 68 65 Section 7.03. Sole Remedy for a Failure to Report 68 65 Section 7.04. Other Remedies 70 67 Section 7.05. Waiver of Past Defaults 70 67 Section 7.06. Control by Majority 70 67 Section 7.07. Limitation on Suits 70 67 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 68 Section 7.09. Collection Suit by Trustee 71 68 Section 7.10. Trustee May File Proofs of Claim 71 68 Section 7.11. Priorities 72 69 Section 7.12. Undertaking for Costs 72 69 Section 7.13. Restoration of Rights 70 Article 8. Amendments, Supplements and Waivers 73 70 Section 8.01. Without the Consent of Holders 73 70 Section 8.02. With the Consent of Holders 74 71 Section 8.03. Notice of Amendments, Supplements and Waivers 75 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 Section 8.05. Notations and Exchanges 76 Section 8.06. Trustee to Execute Supplemental Indentures 76 Article 9. Satisfaction and Discharge 76 Section 9.01. Termination of Company’s Obligations 76 Section 9.02. Repayment to Company 77 Section 9.03. Reinstatement 77 Article 10. Trustee 77 Section 10.01. Duties of the Trustee 77 Section 10.02. Rights of the Trustee 79 Section 10.03. Individual Rights of the Trustee 80 Section 10.04. Trustee’s Disclaimer 80 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 Section 10.07. Replacement of the Trustee 81 Section 10.08. Successor Trustee by Xxxxxx, Etc. 82 Section 10.09. Eligibility; Disqualification 83 Article 11. Miscellaneous 83 Section 11.01. Notices 83 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 Section 11.04. Rules by the Trustee, the Registrar, the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).72
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 18 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 19 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 26 Section 2.16. Notes Held by the Company or its Affiliates 27 26 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX and ISIN CUSIP Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 28 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 30 Section 3.06. Stay, Extension and Usury Laws 31 30 Section 3.07. Corporate Existence 31 Section 3.08. Restriction on Acquisition of Notes by the Company and its Affiliates 32 31 Section 3.09. Further Instruments and Acts 31 Article 4. Repurchase and Redemption 32 31 Section 4.01. No Sinking Fund 32 31 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 31 Section 4.03. Right of the Company to Redeem the Notes 36 35 Article 5. Conversion 39 38 Section 5.01. Right to Convert 39 38 Section 5.02. Conversion Procedures 43 41 Section 5.03. Settlement Upon upon Conversion 45 43 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 46 Section 5.05. Adjustments to the Conversion Rate 49 46 Section 5.06. Voluntary Adjustments 60 58 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 58 Section 5.08. Exchange in Lieu of Conversion 62 59 Section 5.09. Effect of Common Stock Change Event 63 60 Article 6. Successors 65 62 Section 6.01. When the Company May Merge, Etc. 65 62 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 62 Article 7. Defaults and Remedies 66 63 Section 7.01. Events of Default 66 63 Section 7.02. Acceleration 68 65 Section 7.03. Sole Remedy for a Failure to Report 68 65 Section 7.04. Other Remedies 70 66 Section 7.05. Waiver of Past Defaults 70 66 Section 7.06. Control by Majority 70 67 Section 7.07. Limitation on Suits 70 67 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 68 Section 7.09. Collection Suit by Trustee 71 68 Section 7.10. Trustee May File Proofs of Claim 71 68 Section 7.11. Priorities 72 69 Section 7.12. Undertaking for Costs 72 69 Section 7.13. Restoration of Rights 69 Article 8. Amendments, Supplements and Waivers 73 70 Section 8.01. Without the Consent of Holders 73 70 Section 8.02. With the Consent of Holders 74 71 Section 8.03. Notice of Amendments, Supplements and Waivers 75 72 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 72 Section 8.05. Notations and Exchanges 76 72 Section 8.06. Trustee to Execute Supplemental Indentures 76 73 Article 9. Satisfaction and Discharge 76 73 Section 9.01. Termination of Company’s Obligations 76 73 Section 9.02. Repayment to Company 77 74 Section 9.03. Reinstatement 77 74 Article 10. Trustee 77 74 Section 10.01. Duties of the Trustee 77 74 Section 10.02. Rights of the Trustee 79 75 Section 10.03. Individual Rights of the Trustee 80 77 Section 10.04. Trustee’s Disclaimer 80 77 Section 10.05. Notice of Defaults 80 77 Section 10.06. Compensation and Indemnity 81 77 Section 10.07. Replacement of the Trustee 81 78 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 79 Section 10.09. Eligibility; Disqualification 83 79 Article 11. Miscellaneous 83 79 Section 11.01. Notices 83 79 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 81 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 81 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).82
Appears in 1 contract
Samples: Indenture (Pegasystems Inc)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Exchange Agent 18 Section 2.07. Paying Agent and Conversion Exchange Agent to Hold Property in Trust 18 19 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted Exchanged or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 Replacement Notes 25 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 25 Section 2.14. Cancellation 25 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 25 Section 2.16. Temporary Notes 26 Section 2.17. Temporary Outstanding Notes 27 26 Section 2.18. Outstanding Notes 28 Section 2.19. Repurchases by the Company 28 27 Section 2.202.19. XXXXX CUSIP and ISIN Numbers 29 27 Article 3. Covenants 29 27 Section 3.01. Payment on Notes 29 27 Section 3.02. Exchange Act Reports 29 27 Section 3.03. Rule 144A Information 30 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 28 Section 3.063.04. Stay, Extension and Usury Laws 31 28 Section 3.073.05. Acquisition of Notes by the Company and its Affiliates 32 28 Article 4. Repurchase and Redemption 32 28 Section 4.01. No Sinking Fund 32 28 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 29 Section 4.03. Right of the Company to Redeem the Notes 36 33 Article 5. Conversion 39 Exchange 36 Section 5.01. Right to Convert 39 Exchange 36 Section 5.02. Conversion Exchange Procedures 43 40 Section 5.03. Settlement Upon Conversion 45 Exchange 41 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 Exchange 45 Section 5.05. Adjustments to the Conversion Exchange Rate 49 46 Section 5.06. Voluntary Adjustments 60 56 Section 5.07. Adjustments to the Conversion Exchange Rate in Connection with a Make-Whole Fundamental Change 61 56 Section 5.08. Exchange in Lieu Transfer of Conversion 62 Notes to Be Exchanged to a Third Party for Settlement 58 Section 5.09. Effect of Common Stock Change Event 63 58 Article 6. Successors 65 60 Section 6.01. When the Company May Merge, Etc. 65 60 Section 6.02. Successor Entity Substituted 65 61 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 61 Article 7. Defaults and Remedies 66 61 Section 7.01. Events of Default 66 61 Section 7.02. Acceleration 68 63 Section 7.03. Sole Remedy for a Failure to Report 68 64 Section 7.04. Other Remedies 70 65 Section 7.05. Waiver of Past Defaults 70 65 Section 7.06. Control by Majority 70 65 Section 7.07. Limitation on Suits 70 66 Section 7.08. Absolute Right of Holders to Receive Payment and Exchange Consideration and to Institute Suit for the Enforcement of the such Right to Receive Payment and Conversion Consideration 71 66 Section 7.09. Collection Suit by Trustee 71 66 Section 7.10. Trustee May File Proofs of Claim 71 67 Section 7.11. Priorities 72 67 Section 7.12. Undertaking for Costs 72 68 Article 8. Amendments, Supplements and Waivers 73 68 Section 8.01. Without the Consent of Holders 73 68 Section 8.02. With the Consent of Holders 74 69 Section 8.03. Notice of Amendments, Supplements and Waivers 75 70 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 70 Section 8.05. Notations and Exchanges 76 71 Section 8.06. Trustee to Execute Supplemental Indentures 71 Article 9. Guarantees 72 Section 9.01. Guarantees 72 Section 9.02. Limitation on Guarantor Liability 73 Section 9.03. Execution and Delivery of Guarantee 73 Section 9.04. When the Guarantors May Merge, Etc. 73 Section 9.05. Future Guarantors 75 Section 9.06. Application of Certain Provisions to the Guarantors 76 Section 9.07. Release of Guarantees 76 Article 910. Satisfaction and Discharge 76 77 Section 9.0110.01. Termination of Company’s and Guarantors’ Obligations 76 77 Section 9.0210.02. Repayment to Company 77 Section 9.0310.03. Reinstatement 77 78 Article 1011. Trustee 77 78 Section 10.0111.01. Duties of the Trustee 77 78 Section 10.0211.02. Rights of the Trustee 79 Section 10.0311.03. Individual Rights of the Trustee 80 Section 10.0411.04. Trustee’s Disclaimer 80 Section 10.0511.05. Notice of Defaults 80 Section 10.0611.06. Compensation and Indemnity 81 80 Section 10.0711.07. Replacement of the Trustee 81 Section 10.0811.08. Successor Trustee by XxxxxxMerger, Etc. 82 Section 10.0911.09. Eligibility; Disqualification 83 82 Article 1112. Miscellaneous 83 82 Section 11.0112.01. Notices 83 82 Section 11.0212.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 84 Section 11.0312.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 Section 11.0412.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 Section 11.0512.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 85 Section 11.0612.06. Governing Law; Waiver of Jury Trial 86 85 Section 11.0712.07. Submission to Jurisdiction 86 Section 11.0812.08. No Adverse Interpretation of Other Agreements 86 Section 11.0912.09. Successors 86 Section 11.1012.10. Force Majeure 87 86 Section 11.1112.11. U.S.A. PATRIOT Act 87 86 Section 11.1212.12. Calculations 87 Section 11.1312.13. Severability 87 Section 11.1412.14. Counterparts 87 Section 11.1512.15. Table of Contents, Headings, Etc. 88 87 Section 11.1612.16. Withholding Taxes 87 Section 12.17. Trust Indenture Act Controls 88 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Global Note Legend B1-1 Exhibit B-2: Form of Global Note Affiliate Resale Legend B2-1 Exhibit B-3: Form Trust Indenture Act Section Indenture Section 310(a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311(a) N/A (b) N/A (c) N/A 312(a) 2.08 (b) N/A (c) N/A 313(a) N/A (b)(1) N/A (b)(2) N/A (c) N/A (d) N/A 314(a) 3.02(A) (b) N/A (c)(1) 12.02(A) (c)(2) 12.02(B) (c)(3) N/A (d) N/A (e) 12.02(A), 12.02(B) (f) N/A 315(a) N/A (b) N/A (c) N/A (d) N/A (e) 7.12 316(a) (last sentence) 2.15 (a)(1)(A) 7.06 (a)(1)(B) 7.05 (a)(2) N/A (b) 7.08 (c) N/A 317(a)(1) 7.09 (a)(2) 7.10 (b) 2.07 318(a) N/A (b) 12.17 (c) N/A N/A means not applicable. * This Cross Reference Table is not part of Affiliate Resale Legend B3-1 the Indenture. FIRST SUPPLEMENTAL INDENTURE, dated as of April 17March 19, 20232021, between Mirum Pharmaceuticalsamong Centennial Resource Production, Inc.LLC, a Delaware corporationlimited liability company, as issuer (the “Company”), the Guarantor parties signatory hereto and U.S. Bank Trust CompanyUMB Bank, National AssociationN.A., as trustee (the “Trustee”), to the Base Indenture (as defined below). Each party to this This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Article II of the Base Indenture to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 3.25% Exchangeable Senior Notes due 2028 (the “Notes”). Each party to this Supplemental Indenture agrees as follows for the benefit of the other party parties and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).
Appears in 1 contract
Samples: First Supplemental Indenture (Centennial Resource Development, Inc.)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Exchange Agent 18 Section 2.07. Paying Agent and Conversion Exchange Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted Exchanged or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.142.13. Registered Holders; Certain Rights with Respect to Global Notes 27 Section 2.152.14. Cancellation 27 Section 2.162.15. Notes Held by the Company or its Affiliates 27 Section 2.172.16. Temporary Notes 27 Section 2.182.17. Outstanding Notes 28 27 Section 2.192.18. Repurchases by the Company 28 Section 2.202.19. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 Section 3.01. Payment on Notes 29 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 Section 3.05. Maturity Premium 30 Section 3.06. Compliance and Default Certificates 31 Section 3.063.07. Stay, Extension and Usury Laws 31 Section 3.073.08. Acquisition of Notes by the Company Company, the Guarantor and its their Respective Affiliates 32 31 Article 4. Repurchase and Redemption 32 Section 4.01. No Sinking Fund 32 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon a Fundamental Change 32 Section 4.03. No Right of Redemption by the Company to Redeem the Notes 36 Article 5. Conversion 39 Exchange 36 Section 5.01. Right to Convert 39 Exchange 36 Section 5.02. Conversion Exchange Procedures 43 40 Section 5.03. Settlement Upon Conversion 45 Exchange 42 Section 5.04. Reserve and Status of Common Stock Issued Delivered Upon Conversion 49 Exchange 45 Section 5.05. Adjustments to the Conversion Exchange Rate 49 46 Section 5.06. Voluntary Adjustments 60 55 Section 5.07. Adjustments to the Conversion Exchange Rate in Connection with a Make-Whole Fundamental Change 61 56 Section 5.08. Exchange in Lieu Transfer of Conversion 62 Notes to Be Exchanged to a Third Party for Settlement 57 Section 5.09. Effect of Common Stock Change Event 63 58 Section 5.10. Deemed Representation Upon Exchange 60 Article 6. Successors 65 60 Section 6.01. When the Company May Merge, Etc. 65 60 Section 6.02. Company Successor Entity Substituted 65 60 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 61 Article 7. Defaults and Remedies 66 61 Section 7.01. Events of Default 66 61 Section 7.02. Acceleration 68 63 Section 7.03. Sole Remedy for a Failure to Report 68 64 Section 7.04. Other Remedies 70 65 Section 7.05. Waiver of Past Defaults 70 65 Section 7.06. Control by Majority 70 65 Section 7.07. Limitation on Suits 70 65 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Exchange Consideration 71 66 Section 7.09. Collection Suit by Trustee 71 66 Section 7.10. Trustee May File Proofs of Claim 71 66 Section 7.11. Priorities 72 67 Section 7.12. Undertaking for Costs 72 67 Article 8. Amendments, Supplements and Waivers 73 68 Section 8.01. Without the Consent of Holders 73 68 Section 8.02. With the Consent of Holders 74 69 Section 8.03. Notice of Amendments, Supplements and Waivers 75 70 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 70 Section 8.05. Notations and Exchanges 76 71 Section 8.06. Trustee to Execute Supplemental Indentures 76 71 Article 9. Guarantee 72 Section 9.01. Guarantee 72 Section 9.02. Limitation on Guarantor Liability 73 Section 9.03. Execution and Delivery of Guarantee 73 Section 9.04. When the Guarantor May Merge, Etc. 74 Section 9.05. Application of Certain Provisions to the Guarantor 75 Section 9.06. Release of the Guarantee 75 Article 10. Satisfaction and Discharge 76 75 Section 9.0110.01. Termination of Company’s Obligations 76 75 Section 9.0210.02. Repayment to Company 77 76 Section 9.0310.03. Reinstatement 77 76 Article 1011. Trustee 77 76 Section 10.0111.01. Duties of the Trustee 76 Section 11.02. Rights of the Trustee 77 Section 10.0211.03. Individual Rights of the Trustee 79 Section 10.0311.04. Individual Rights Trustee’s Disclaimer 79 Section 11.05. Notice of Defaults 79 Section 11.06. Compensation and Indemnity 79 Section 11.07. Replacement of the Trustee 80 Section 10.04. Trustee’s Disclaimer 80 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 Section 10.07. Replacement of the Trustee 81 Section 10.0811.08. Successor Trustee by Xxxxxx, Etc. 82 81 Section 10.0911.09. Eligibility; Disqualification 83 81 Article 1112. Miscellaneous 83 82 Section 11.0112.01. Notices 83 82 Section 11.0212.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 84 Section 11.0312.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 84 Section 11.0412.04. Rules by the Trustee, the Registrar, the Paying Agent and the Conversion Exchange Agent 85 84 Section 11.0512.05. No Personal Liability of Directors, Officers, Employees Employees, Partners and Stockholders 86 84 Section 11.0612.06. Governing Law; Waiver of Jury Trial 86 85 Section 11.0712.07. Submission to Jurisdiction 86 85 Section 11.0812.08. No Adverse Interpretation of Other Agreements 86 85 Section 11.0912.09. Successors 86 85 Section 11.1012.10. Force Majeure 87 85 Section 11.1112.11. U.S.A. PATRIOT Act 87 86 Section 11.1212.12. Calculations 87 86 Section 11.1312.13. Severability 87 86 Section 11.1412.14. Counterparts 87 86 Section 11.1512.15. Table of Contents, Headings, Etc. 88 86 Section 11.1612.16. Withholding Taxes 88 87 Exhibit AA : Form of Note A-1 Exhibit B-1B-1 : Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17March 28, 20232024, between Mirum Pharmaceuticalsamong Xxxxxxx Industrial Realty, Inc.L.P., a Delaware corporationMaryland limited partnership, as issuer (the “Company”), Xxxxxxx Industrial Realty, Inc., a Maryland corporation, as guarantor (the “Guarantor”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party parties and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.004.375% Convertible Exchangeable Senior Notes due 2029 2027 (the “Notes”).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 26 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 28 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 29 Section 3.05. Additional Amounts 30 Section 3.053.06. Compliance and Default Certificates 31 33 Section 3.063.07. Stay, Extension and Usury Laws 31 33 Section 3.073.08. Acquisition of Notes Acquired by the Company and its Affiliates 32 33 Section 3.09. Existence 33 Article 4. Repurchase and Redemption 32 33 Section 4.01. No Sinking Fund 32 33 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 34 Section 4.03. Right of the Company to Redeem the Notes 36 38 Article 5. Conversion 39 43 Section 5.01. Right to Convert 39 43 Section 5.02. Conversion Procedures 43 47 Section 5.03. Settlement Upon upon Conversion 45 48 Section 5.04. Reserve and Status of Common Stock Ordinary Shares Issued Upon upon Conversion 49 51 Section 5.05. Adjustments to the Conversion Rate 49 52 Section 5.06. Voluntary Adjustments 60 62 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 63 Section 5.08. Exchange in Lieu of Conversion 62 64 Section 5.09. Effect of Common Stock Ordinary Share Change Event 63 65 Article 6. Successors 65 67 Section 6.01. When the Company May Merge, Etc. 65 67 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 67 Article 7. Defaults and Remedies 66 67 Section 7.01. Events of Default 66 67 Section 7.02. Acceleration 68 69 Section 7.03. Sole Remedy for a Failure to Report 68 70 Section 7.04. Other Remedies 70 71 Section 7.05. Waiver of Past Defaults 70 71 Section 7.06. Control by Majority 70 72 Section 7.07. Limitation on Suits 70 72 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 72 Section 7.09. Collection Suit by Trustee 71 73 Section 7.10. Trustee May File Proofs of Claim 71 73 Section 7.11. Priorities 72 73 Section 7.12. Undertaking for Costs 72 74 Article 8. Amendments, Supplements and Waivers 73 74 Section 8.01. Without the Consent of Holders 73 74 Section 8.02. With the Consent of Holders 74 75 Section 8.03. Notice of Amendments, Supplements and Waivers 75 76 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 76 Section 8.05. Notations and Exchanges 76 77 Section 8.06. Trustee to Execute Supplemental Indentures 76 77 Article 9. Satisfaction and Discharge 76 77 Section 9.01. Termination of Company’s Obligations 76 77 Section 9.02. Repayment to Company 77 78 Section 9.03. Reinstatement 77 78 Article 10. Trustee 77 79 Section 10.01. Duties of the Trustee 77 79 Section 10.02. Rights of the Trustee 79 80 Section 10.03. Individual Rights of the Trustee 80 81 Section 10.04. Trustee’s Disclaimer 80 82 Section 10.05. Notice of Defaults 80 82 Section 10.06. Compensation and Indemnity 81 82 Section 10.07. Replacement of the Trustee 81 83 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 84 Section 10.09. Eligibility; Disqualification 83 84 Article 11. Miscellaneous 83 84 Section 11.01. Notices 83 84 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 86 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 86 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 86 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Shareholders 87 Section 11.06. Governing Law; Waiver of Jury Trial 86 87 Section 11.07. Submission to Jurisdiction 86 87 Section 11.08. No Adverse Interpretation of Other Agreements 86 87 Section 11.09. Successors 86 87 Section 11.10. Force Majeure 87 88 Section 11.11. U.S.A. PATRIOT Act 87 88 Section 11.12. Calculations 87 88 Section 11.13. Severability 87 88 Section 11.14. Counterparts 87 89 Section 11.15. Table of Contents, Headings, Etc. 88 89 Section 11.16. Withholding Taxes 88 [Reserved] 89 Section 11.17. Foreign Account Tax Compliance Act (FATCA) 89 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17February 11, 20232020, between Mirum PharmaceuticalsSMART Global Holdings, Inc., a Delaware corporationCayman Islands exempted company, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”as defined below).
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 Section 3.01. Payment on Notes 29 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 Section 3.06. Stay, Extension and Usury Laws 31 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 31 Article 4. Repurchase and Redemption 32 31 Section 4.01. No Sinking Fund 32 31 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 Section 4.03. Right of the Company to Redeem the Notes 36 Article 5. Conversion 39 Section 5.01. Right to Convert 39 Section 5.02. Conversion Procedures 43 Section 5.03. Settlement Upon upon Conversion 45 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 48 Section 5.05. Adjustments to the Conversion Rate 49 Section 5.06. Voluntary Adjustments 60 59 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 60 Section 5.08. Exchange in Lieu of Conversion 62 61 Section 5.09. Effect of Common Stock Change Event 63 62 Article 6. Successors 65 64 Section 6.01. When the Company May Merge, Etc. 65 64 Section 6.02. Successor Entity Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 64 Article 7. Defaults and Remedies 66 64 Section 7.01. Events of Default 66 64 Section 7.02. Acceleration 68 67 Section 7.03. Sole Remedy for a Failure to Report 68 67 Section 7.04. Other Remedies 70 68 Section 7.05. Waiver of Past Defaults 70 68 Section 7.06. Control by Majority 70 69 Section 7.07. Limitation on Suits 70 69 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 70 Section 7.09. Collection Suit by Trustee 71 70 Section 7.10. Trustee May File Proofs of Claim 71 70 Section 7.11. Priorities 72 71 Section 7.12. Undertaking for Costs 72 71 Article 8. Amendments, Supplements and Waivers 73 71 Section 8.01. Without the Consent of Holders 73 71 Section 8.02. With the Consent of Holders 74 72 Section 8.03. Notice of Amendments, Supplements and Waivers 75 73 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 74 Section 8.05. Notations and Exchanges 76 74 Section 8.06. Trustee to Execute Supplemental Indentures 76 75 Article 9. Satisfaction and Discharge 76 75 Section 9.01. Termination of Company’s Obligations 76 75 Section 9.02. Repayment to Company 77 76 Section 9.03. Reinstatement 77 76 Article 10. Trustee 77 76 Section 10.01. Duties of the Trustee 77 76 Section 10.02. Rights of the Trustee 79 77 Section 10.03. Individual Rights of the Trustee 80 78 Section 10.04. Trustee’s Disclaimer 80 79 Section 10.05. Notice of Defaults 80 79 Section 10.06. Compensation and Indemnity 81 79 Section 10.07. Replacement of the Trustee 81 80 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 81 Section 10.09. Eligibility; Disqualification 83 81 Article 11. Miscellaneous 83 81 Section 11.01. Notices 83 81 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 83 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 83 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 84 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 84 Section 11.06. Governing Law; Waiver of Jury Trial 86 84 Section 11.07. Submission to Jurisdiction 86 84 Section 11.08. No Adverse Interpretation of Other Agreements 86 84 Section 11.09. Successors 86 85 Section 11.10. Force Majeure 87 85 Section 11.11. U.S.A. PATRIOT Act 87 85 Section 11.12. Calculations 87 85 Section 11.13. Severability 87 85 Section 11.14. Counterparts 87 86 Section 11.15. Table of Contents, Headings, Etc. 88 86 Section 11.16. Withholding Taxes 88 86 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17September 28, 20232020, between Mirum PharmaceuticalsZogenix, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.002.75% Convertible Senior Notes due 2029 2027 (the “Notes”).
Appears in 1 contract
Samples: Indenture (Zogenix, Inc.)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 11 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 11 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 12 Section 2.08. Holder Lists 19 12 Section 2.09. Legends 19 12 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 12 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 15 Section 2.12. Removal of Transfer Restrictions 26 Replacement Notes 15 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 15 Section 2.14. Cancellation 16 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 16 Section 2.16. Temporary Notes 16 Section 2.17. Temporary Outstanding Notes 27 16 Section 2.18. Outstanding Notes 28 Section 2.19. Repurchases by the Company 28 17 Section 2.202.19. XXXXX CUSIP and ISIN Numbers 29 17 Article 3. Covenants 29 COVENANTS 17 Section 3.01. Payment on Notes 29 17 Section 3.02. Exchange Act Reports 29 17 Section 3.03. Rule 144A Information 30 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 17 Section 3.063.04. Stay, Extension and Usury Laws 31 18 Section 3.073.05. Corporate Existence 18 Section 3.06. Acquisition of Notes by the Company and its Affiliates 32 18 Section 3.07. Further Instruments and Acts 18 Article 4. Repurchase and Redemption 32 REPURCHASE AND REDEMPTION 18 Section 4.01. No Sinking Fund 32 18 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 18 Section 4.03. Right of the Company to Redeem the Notes 36 21 Article 5. Conversion 39 CONVERSION 23 Section 5.01. Right to Convert 39 23 Section 5.02. Conversion Procedures 43 23 Section 5.03. Settlement Upon upon Conversion 45 24 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 25 Section 5.05. Adjustments to the Conversion Rate 49 25 Section 5.06. Voluntary Adjustments 60 31 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 31 Section 5.08. Exchange in Lieu of Conversion 62 Section 5.09. Effect of Common Stock Change Event 63 32 Section 5.09. Limits Upon Issuance of Shares of Common Stock Upon Conversion 33 Article 6. Successors 65 SUCCESSORS 34 Section 6.01. When the Company May Merge, Etc. 65 34 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 35 Article 7. Defaults and Remedies 66 DEFAULTS AND REMEDIES 35 Section 7.01. Events of Default 66 35 Section 7.02. Acceleration 68 36 Section 7.03. Sole Remedy for a Failure to Report 68 37 Section 7.04. Other Remedies 70 37 Section 7.05. Waiver of Past Defaults 70 38 Section 7.06. Control by Majority 70 38 Section 7.07. Limitation on Suits 70 38 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 38 Section 7.09. Collection Suit by Trustee 71 38 Section 7.10. Trustee May File Proofs of Claim 71 39 Section 7.11. Priorities 72 39 Section 7.12. Undertaking for Costs 72 39 Section 7.13. Trustee’s Obligation to Provide Notice of Defaults to Holders 39 Article 8. AmendmentsAMENDMENTS, Supplements and Waivers 73 SUPPLEMENTS AND WAIVERS 40 Section 8.01. Without the Consent of Holders 73 40 Section 8.02. With the Consent of Holders 74 40 Section 8.03. Notice of Amendments, Supplements and Waivers 75 41 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 41 Section 8.05. Notations and Exchanges 76 41 Section 8.06. Trustee to Execute Supplemental Indentures 76 42 Article 9. Satisfaction and Discharge 76 SATISFACTION AND DISCHARGE 42 Section 9.01. Termination of Company’s Obligations 76 42 Section 9.02. Repayment to Company 77 42 Section 9.03. Reinstatement 77 42 Article 10. Trustee 77 TRUSTEE 43 Section 10.01. Duties of the Trustee 77 43 Section 10.02. Rights of the Trustee 79 44 Section 10.03. Individual Rights of the Trustee 80 44 Section 10.04. Trustee’s Disclaimer 80 45 Section 10.05. Notice of Defaults 80 45 Section 10.06. Compensation and Indemnity 81 45 Section 10.07. Replacement of the Trustee 81 45 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 46 Section 10.09. Eligibility; Disqualification 83 46 Article 11. Miscellaneous 83 MISCELLANEOUS 46 Section 11.01. Notices 83 46 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 47 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 48 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 48 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 48 Section 11.06. Governing Law; Waiver of Jury Trial 86 48 Section 11.07. Submission to Jurisdiction 86 48 Section 11.08. No Adverse Interpretation of Other Agreements 86 49 Section 11.09. Successors 86 49 Section 11.10. Force Majeure 87 49 Section 11.11. U.S.A. PATRIOT Act 87 49 Section 11.12. Calculations 87 49 Section 11.13. Severability 87 49 Section 11.14. Counterparts 87 49 Section 11.15. Table of Contents, Headings, Etc. 88 49 Section 11.16. Withholding Taxes 88 50 Section 11.17. Trust Indenture Act Controls 50 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2B: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 B-1 FIRST SUPPLEMENTAL INDENTURE, dated as of April 17June 30, 20232020, between Mirum Xeris Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Sections 2.01 and 2.02 of the Base Indenture (as defined below) to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”). Each party to this Supplemental Indenture agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).
Appears in 1 contract
Samples: First Supplemental Indenture (Xeris Biopharma Holdings, Inc.)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX and ISIN Numbers 29 Article 3. Covenants 29 Section 3.01. Payment on Notes 29 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 Section 3.04. Additional Interest 30 Section 3.05. Compliance and Default Certificates 31 Section 3.06. Stay, Extension and Usury Laws 31 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 Article 4. Repurchase and Redemption 32 Section 4.01. No Sinking Fund 32 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 Section 4.03. Right of the Company to Redeem the Notes 36 37 Article 5. Conversion 39 40 Section 5.01. Right to Convert 39 40 Section 5.02. Conversion Procedures 43 44 Section 5.03. Settlement Upon upon Conversion 45 Section 5.04. Reserve and Status of Class A Common Stock Issued Upon upon Conversion 49 Section 5.05. Adjustments to the Conversion Rate 49 50 Section 5.06. Voluntary Adjustments 60 61 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 Section 5.08. Exchange in Lieu of Conversion 62 Section 5.09. Effect of Common Stock Change Event 63 Article 6. Successors 65 Section 6.01. When the Company May Merge, Etc. 65 Section 6.02. Successor Entity Substituted 65 66 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 66 Article 7. Defaults and Remedies 66 Section 7.01. Events of Default 66 Section 7.02. Acceleration 68 Section 7.03. Sole Remedy for a Failure to Report 68 Section 7.04. Other Remedies 70 69 Section 7.05. Waiver of Past Defaults 70 Section 7.06. Control by Majority 70 Section 7.07. Limitation on Suits 70 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 Section 7.09. Collection Suit by Trustee 71 Section 7.10. Trustee May File Proofs of Claim 71 Section 7.11. Priorities 72 Section 7.12. Undertaking for Costs 72 Article 8. Amendments, Supplements and Waivers 73 Section 8.01. Without the Consent of Holders 73 Section 8.02. With the Consent of Holders 74 Section 8.03. Notice of Amendments, Supplements and Waivers 75 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 Section 8.05. Notations and Exchanges 76 Section 8.06. Trustee to Execute Supplemental Indentures 76 Article 9. Satisfaction and Discharge 76 Section 9.01. Termination of Company’s Obligations 76 Section 9.02. Repayment to Company 77 Section 9.03. Reinstatement 77 Article 10. Trustee 77 Section 10.01. Duties of the Trustee 77 Section 10.02. Rights of the Trustee 79 Section 10.03. Individual Rights of the Trustee 80 Section 10.04. Trustee’s Disclaimer 80 Section 10.05. Notice of Defaults 80 Section 10.06. Compensation and Indemnity 81 Section 10.07. Replacement of the Trustee 81 82 Section 10.08. Successor Trustee by Xxxxxx, Etc. 82 83 Section 10.09. Eligibility; Disqualification 83 Article 11. Miscellaneous 83 Section 11.01. Notices 83 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 85 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 86 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17May 16, 2023, between Mirum Pharmaceuticals, Inc.Bloom Energy Corporation, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.003.00% Green Convertible Senior Notes due 2029 2028 (the “Notes”).
Appears in 1 contract
Samples: Indenture (Bloom Energy Corp)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 35 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 36 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 37 Section 2.08. Holder Lists 19 37 Section 2.09. Legends 19 37 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 38 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 42 Section 2.12. Removal of Transfer Restrictions 26 43 Section 2.13. Replacement Notes 26 43 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 43 Section 2.15. Cancellation 27 44 Section 2.16. Notes Held by the Company or its Affiliates 27 44 Section 2.17. Temporary Notes 27 44 Section 2.18. Outstanding Notes 28 44 Section 2.19. Repurchases by the Company 28 45 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 45 Article 3. Covenants 29 46 Section 3.01. Payment on Notes 29 46 Section 3.02. Exchange Act Reports 29 46 Section 3.03. Rule 144A Information 30 46 Section 3.04. Additional Interest 30 47 Section 3.05. Compliance and Default Certificates 31 47 Section 3.06. Stay, Extension and Usury Laws 31 48 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 48 Section 3.08. Restricted Payments 48 Section 3.09. Dividend and Other Payment Restrictions Affecting Subsidiaries 52 Section 3.10. Incurrence of Indebtedness and Issuance of Preferred Stock 53 Section 3.11. Asset Sales 59 Section 3.12. Transactions with Affiliates 59 Section 3.13. Liens 60 Section 3.14. Additional Guarantees 61 Section 3.15. [Reserved] 61 Section 3.16. After-Acquired Property 61 Section 3.17. Limitation on Issuance of Equity Interests 62 Section 3.18. Collateral 62 Section 3.19. Taxes 62 Section 3.20. Holding Company Status 62 Section 3.21. Payments for Consents 63 Section 3.22. Most Favored Nations 64 Article 4. Repurchase and Redemption 32 65 Section 4.01. No Sinking Fund 32 65 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 65 Section 4.03. Right of the Company to Redeem the Notes 36 69 Article 5. Conversion 39 72 Section 5.01. Right to Convert 39 72 Section 5.02. Conversion Procedures 43 73 Section 5.03. Settlement Upon upon Conversion 45 75 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 Shares to be Fully Paid 78 Section 5.05. Adjustments to the Conversion Rate 49 79 Section 5.06. Voluntary Adjustments 60 89 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 89 Section 5.08. Exchange in Lieu of Conversion 62 [Reserved.] 91 Section 5.09. Effect of Common Stock Change Event 63 91 Section 5.10. Responsibility of Trustee and Conversion Agent 93 Article 6. Successors 65 95 Section 6.01. When the Company May Merge, Etc. 65 95 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 95 Article 7. Defaults and Remedies 66 96 Section 7.01. Events of Default 66 96 Section 7.02. Acceleration 68 98 Section 7.03. Sole Remedy for a Failure to Report 68 98 Section 7.04. Other Remedies 70 99 Section 7.05. Waiver of Past Defaults 70 99 Section 7.06. Control by Majority 70 100 Section 7.07. Limitation on Suits 70 100 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 101 Section 7.09. Collection Suit by Trustee 71 101 Section 7.10. Trustee May File Proofs of Claim 71 101 Section 7.11. Priorities 72 102 Section 7.12. Undertaking for Costs 72 102 Article 8. Amendments, Supplements and Waivers 73 103 Section 8.01. Without the Consent of Holders 73 103 Section 8.02. With the Consent of Holders 74 104 Section 8.03. Notice of Amendments, Supplements and Waivers 75 105 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 105 Section 8.05. Notations and Exchanges 76 106 Section 8.06. Trustee to Execute Supplemental Indentures 76 106 Article 9. Guarantees 106 Section 9.01. Guarantees 106 Section 9.02. Limitation on Guarantor Liability 108 Section 9.03. Execution and Delivery of Guarantee 108 Section 9.04. When Guarantors May Merge, etc 108 Section 9.05. Application of Certain Provisions of the Guarantors 109 Section 9.06. Release of Guarantees 109 Article 10. Satisfaction and Discharge 76 110 Section 9.0110.01. Termination of Company’s Obligations 76 110 Section 9.0210.02. Repayment to Company 77 111 Section 9.0310.03. Reinstatement 77 Reinstatement. 111 Article 1011. Trustee 77 111 Section 10.0111.01. Duties of the Trustee 77 111 Section 10.0211.02. Rights of the Trustee 79 112 Section 10.0311.03. Individual Rights of the Trustee 80 113 Section 10.0411.04. Trustee’s Disclaimer 80 114 Section 10.0511.05. Notice of Defaults 80 114 Section 10.0611.06. Compensation and Indemnity 81 114 Section 10.0711.07. Replacement of the Trustee 81 115 Section 10.0811.08. Successor Trustee by XxxxxxMerger, Etc. 82 116 Section 10.0911.09. Eligibility; Disqualification 83 116 Article 1112. Miscellaneous 83 Collateral and Security 116 Section 11.0112.01. Notices 83 Security Documents 116 Section 11.0212.02. Delivery Recording and Opinions 117 Section 12.03. Release of Officer’s Certificate Collateral 117 Section 12.04. Specified Releases of Collateral 118 Section 12.05. Release upon Satisfaction and Opinion Discharge or Amendment 119 Section 12.06. Form and Sufficiency of Counsel as Release and Subordination 119 Section 12.07. Purchaser Protected 119 Section 12.08. Authorization of Actions to Conditions Precedent 85 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 Section 11.04. Rules be Taken by the Trustee, Collateral Agent Under the Registrar, the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).Security Documents 120
Appears in 1 contract
Samples: Indenture (Starry Holdings, Inc.)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 16 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 17 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 18 Section 2.09. Legends 19 18 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 19 Section 2.11. Exchange and Cancellation of Notes to Be Converted Converted, Redeemed or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 24 Section 2.12. Removal of Transfer Restrictions 26 25 Section 2.13. Replacement Notes 26 25 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 25 Section 2.15. Cancellation 27 26 Section 2.16. Notes Held by the Company or its Affiliates 27 26 Section 2.17. Temporary Notes 27 26 Section 2.18. Outstanding Notes 28 26 Section 2.19. Repurchases by the Company 28 27 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 27 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 28 Section 3.03. Rule 144A Information 30 28 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 30 Section 3.06. Stay, Extension and Usury Laws 31 30 Section 3.07. [Reserved] 30 Section 3.08. Restriction on Acquisition of Notes by the Company and its Affiliates 32 Subsidiaries 30 Section 3.09. Further Instruments and Acts 30 Article 4. Repurchase and Redemption 32 30 Section 4.01. No Sinking Fund 32 30 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 31 Section 4.03. Right of the Company to Redeem the Notes 36 35 Article 5. Conversion 39 37 Section 5.01. Right to Convert 39 37 Section 5.02. Conversion Procedures 43 41 Section 5.03. Settlement Upon upon Conversion 45 43 Section 5.04. Reserve and Status of Common Stock Issued Upon upon Conversion 49 46 Section 5.05. Adjustments to the Conversion Rate 49 46 Section 5.06. Voluntary Adjustments 60 57 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 57 Section 5.08. Exchange in Lieu of Conversion 62 58 Section 5.09. Right of Holder to Elect to Limit Delivery of Shares of Common Stock 59 Section 5.10. Effect of Common Stock Change Event 63 60 Section 5.11. Responsibility of Trustee 62 Article 6. Successors 65 62 Section 6.01. When the Company May Merge, Etc. 65 62 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 63 Article 7. Defaults and Remedies 66 63 Section 7.01. Events of Default 66 63 Section 7.02. Acceleration 68 65 Section 7.03. Sole Remedy for a Failure to Report 68 66 Section 7.04. Other Remedies 70 67 Section 7.05. Waiver of Past Defaults 70 67 Section 7.06. Control by Majority 70 67 Section 7.07. Limitation on Suits 70 68 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 68 Section 7.09. Collection Suit by Trustee 71 68 Section 7.10. Trustee May File Proofs of Claim 71 69 Section 7.11. Priorities 72 69 Section 7.12. Undertaking for Costs 72 70 Article 8. Amendments, Supplements and Waivers 73 70 Section 8.01. Without the Consent of Holders 73 70 Section 8.02. With the Consent of Holders 74 71 Section 8.03. Notice of Amendments, Supplements and Waivers 75 72 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 72 Section 8.05. Notations and Exchanges 76 73 Section 8.06. Trustee to Execute Supplemental Indentures 76 73 Article 9. Satisfaction and Discharge 76 73 Section 9.01. Termination of Company’s Obligations 76 73 Section 9.02. Repayment to Company 77 74 Section 9.03. Reinstatement 77 74 Article 10. Trustee 77 75 Section 10.01. Duties of the Trustee 77 75 Section 10.02. Rights of the Trustee 79 76 Section 10.03. Individual Rights of the Trustee 80 77 Section 10.04. Trustee’s Disclaimer 80 77 Section 10.05. Notice of Defaults 80 77 Section 10.06. Compensation and Indemnity 81 77 Section 10.07. Replacement of the Trustee 81 78 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 79 Section 10.09. Eligibility; Disqualification 83 79 Article 11. Miscellaneous 83 80 Section 11.01. Notices 83 80 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 81 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 81 Section 11.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Section 11.06. Governing Law; Waiver of Jury Trial 86 Section 11.07. Submission to Jurisdiction 86 Section 11.08. No Adverse Interpretation of Other Agreements 86 Section 11.09. Successors 86 Section 11.10. Force Majeure 87 Section 11.11. U.S.A. PATRIOT Act 87 Section 11.12. Calculations 87 Section 11.13. Severability 87 Section 11.14. Counterparts 87 Section 11.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.00% Convertible Senior Notes due 2029 (the “Notes”).82
Appears in 1 contract
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 43 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 46 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 47 Section 2.08. Holder Lists 19 47 Section 2.09. Legends 19 47 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 48 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 53 Section 2.12. Removal of Transfer Restrictions 26 [Reserved.] 54 Section 2.13. Replacement Notes 26 54 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 54 Section 2.15. Cancellation 27 55 Section 2.16. Notes Held by the Company or its Affiliates 27 55 Section 2.17. Temporary Notes 27 55 Section 2.18. Outstanding Notes 28 56 Section 2.19. Repurchases by the Company 28 56 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 57 Section 2.21. Registration Rights Agreement 57 Section 2.22. Listing 57 Article 3. Covenants 29 57 Section 3.01. Payment on Notes 29 57 Section 3.02. Exchange Act Reports 29 58 Section 3.03. Rule 144A Information 30 58 Section 3.04. Additional Interest 30 [Reserved.] 59 Section 3.05. Compliance and Default Certificates 31 59 Section 3.06. Stay, Extension and Usury Laws 31 59 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 59 Section 3.08. Limitation on Incurrence of Indebtedness 59 Section 3.09. Limitation on Liens Securing Indebtedness 62 Section 3.10. Limitation on Asset Sales 62 Section 3.11. Limitation on Transactions with Affiliates 63 Section 3.12. Limitation on Restricted Payments 66 Section 3.13. Retention of Cash 71 Section 3.14. Guarantors and Joint Ventures 71 Section 3.15. Material IP 71 Section 3.16. Additional Amounts 72 Article 4. Repurchase and Redemption 32 76 Section 4.01. No Sinking Fund 32 76 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon upon a Fundamental Change 32 76 Section 4.03. Right of the Company to Redeem the Notes 36 80 Section 4.04. Optional Redemption for Changes in the Tax Laws of the Relevant Jurisdiction 83 Article 5. Conversion 39 86 Section 5.01. Right to Convert 39 86 Section 5.02. Conversion Procedures 43 86 Section 5.03. Settlement Upon upon Conversion 45 88 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 to be Fully Paid 89 Section 5.05. Adjustments to the Conversion Rate 49 89 Section 5.06. Voluntary Adjustments 60 [Reserved.] 100 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 [Reserved.] 100 Section 5.08. Exchange in Lieu of Conversion 62 [Reserved.] 100 Section 5.09. Effect of Common Stock Change Event 63 100 Section 5.10. Responsibility of Trustee and Conversion Agent 102 Article 6. Successors 65 103 Section 6.01. When the Company or Guarantors May Merge, Etc. 65 103 Section 6.02. Successor Entity Corporation Substituted 65 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 103 Article 7. Defaults and Remedies 66 103 Section 7.01. Events of Default 66 103 Section 7.02. Acceleration 68 106 Section 7.03. Sole Remedy for a Failure to Report 68 107 Section 7.04. Other Remedies 70 108 Section 7.05. Waiver of Past Defaults 70 108 Section 7.06. Control by Majority 70 108 Section 7.07. Limitation on Suits 70 108 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 109 Section 7.09. Collection Suit by Trustee 71 109 Section 7.10. Trustee May File Proofs of Claim 71 109 Section 7.11. Priorities 72 110 Section 7.12. Undertaking for Costs 72 110 Article 8. Amendments, Supplements and Waivers 73 111 Section 8.01. Without the Consent of Holders 73 111 Section 8.02. With the Consent of Holders 74 112 Section 8.03. Notice of Amendments, Supplements and Waivers 75 113 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 113 Section 8.05. Notations and Exchanges 76 114 Section 8.06. Trustee and Collateral Agent to Execute Supplemental Indentures 76 114 Article 9. Guarantees 114 Section 9.01. Guarantees 114 Section 9.02. Limitation on Guarantor Liability 116 Section 9.03. Execution and Delivery of Guarantee 116 Section 9.04. When Guarantors May Merge, etc. 116 Section 9.05. Application of Certain Provisions of the Guarantors 117 Section 9.06. Release of Guarantees 117 Article 10. Satisfaction and Discharge 76 118 Section 9.0110.01. Termination of Company’s Obligations 76 118 Section 9.0210.02. Repayment to Company 77 119 Section 9.0310.03. Reinstatement 77 119 Article 1011. Trustee 77 119 Section 10.0111.01. Duties of the Trustee 77 119 Section 10.0211.02. Rights of the Trustee 79 121 Section 10.0311.03. Individual Rights of the Trustee 80 122 Section 10.0411.04. Trustee’s Disclaimer 80 123 Section 10.0511.05. Notice of Defaults 80 123 Section 10.0611.06. Compensation and Indemnity 81 123 Section 10.0711.07. Replacement of the Trustee 81 124 Section 10.0811.08. Successor Trustee by XxxxxxMerger, Etc. 82 125 Section 10.0911.09. Eligibility; Disqualification 83 125 Article 1112. Collateral and Security 126 Section 12.01. Security Documents 126 Section 12.02. Recording and Opinions 126 Section 12.03. Release of Collateral 127 Section 12.04. Specified Releases of Collateral 127 Section 12.05. Release upon Satisfaction and Discharge or Amendment 128 Section 12.06. Form and Sufficiency of Release and Subordination 129 Section 12.07. Purchaser Protected 129 Section 12.08. Authorization of Actions to be Taken by the Collateral Agent Under the Security Documents 129 Section 12.09. Authorization of Receipt of Funds by the Trustee Under the Security Documents 131 Section 12.10. Action by the Collateral Agent 131 Section 12.11. Compensation and Indemnity 132 Section 12.12. Post-Closing Collateral 133 Article 13. Miscellaneous 83 133 Section 11.0113.01. Notices 83 133 Section 11.0213.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 135 Section 11.0313.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 135 Section 11.0413.04. Rules by the Trustee, the Registrar, Registrar and the Paying Agent and the Conversion Agent 85 136 Section 11.0513.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 Shareholders 136 Section 11.0613.06. Governing Law; Waiver of Jury Trial 86 136 Section 11.0713.07. Submission to Jurisdiction 86 136 Section 11.0813.08. No Adverse Interpretation of Other Agreements 86 136 Section 11.0913.09. Successors 86 137 Section 11.1013.10. Force Majeure 87 137 Section 11.1113.11. U.S.A. PATRIOT Act 87 137 Section 11.1213.12. Calculations 87 137 Section 11.1313.13. Severability 87 Severability; Entire Agreement 138 Section 11.1413.14. Counterparts 87 138 Section 11.1513.15. Table of Contents, Headings, Etc. 88 Section 11.16. Withholding Taxes 88 138 Exhibit A: Form of Note A-1 Exhibit B-1X-0 Xxxxxxx X-0: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 Exhibit B-4: Form of OID Legend B4-1 Exhibit C: Form of Supplemental Indenture C-1 Exhibit D: Form of Authentication Order D-1 INDENTURE, dated as of April 17[•], 20232022, between Mirum PharmaceuticalsGetaround, Inc., a Delaware corporation, as issuer corporation (the “Company”), and U.S. Bank Trust CompanyBANK TRUST COMPANY, National AssociationNATIONAL ASSOCIATION, as paying agent (in such capacity, the “Paying Agent”), as registrar (in such capacity, the “Registrar”), as trustee (in such capacity, the “Trustee”) and as collateral agent (the “Collateral Agent”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.008.00% / 9.50% Convertible Senior Secured PIK Toggle Notes due 2029 2027 (the “Notes”).
Appears in 1 contract
Samples: Convertible Note Subscription Agreement (InterPrivate II Acquisition Corp.)
Accrual of Interest; Defaulted Amounts. When Payment Date is Not a Business Day 17 Section 2.06. Registrar, Paying Agent and Conversion Agent 18 Section 2.07. Paying Agent and Conversion Agent to Hold Property in Trust 18 Section 2.08. Holder Lists 19 Section 2.09. Legends 19 Section 2.10. Transfers and Exchanges; Certain Transfer Restrictions 20 Section 2.11. Exchange and Cancellation of Notes to Be Converted or to Be Repurchased Pursuant to a Repurchase Upon Fundamental Change or Redemption 25 Section 2.12. Removal of Transfer Restrictions 26 Section 2.13. Replacement Notes 26 Section 2.14. Registered Holders; Certain Rights with Respect to Global Notes 27 26 Section 2.15. Cancellation 27 Section 2.16. Notes Held by the Company or its Affiliates 27 Section 2.17. Temporary Notes 27 Section 2.18. Outstanding Notes 28 27 Section 2.19. Repurchases by the Company 28 Section 2.20. XXXXX CUSIP and ISIN Numbers 29 28 Article 3. Covenants 29 28 Section 3.01. Payment on Notes 29 28 Section 3.02. Exchange Act Reports 29 Section 3.03. Rule 144A Information 30 29 Section 3.04. Additional Interest 30 29 Section 3.05. Compliance and Default Certificates 31 32 Section 3.06. Stay, Extension and Usury Laws 31 32 Section 3.07. Acquisition of Notes by the Company and its Affiliates 32 Section 3.08. Existence 32 Article 4. Repurchase and Redemption 32 Section 4.01. No Sinking Fund 32 Section 4.02. Right of Holders to Require the Company to Repurchase Notes Upon a Fundamental Change 32 33 Section 4.03. Right of the Company to Redeem the Notes 36 37 Article 5. The Conversion 39 of Notes 40 Section 5.01. Right to Convert 39 40 Section 5.02. Conversion Procedures 43 44 Section 5.03. Settlement Upon Conversion 45 Section 5.04. Reserve and Status of Common Stock Issued Upon Conversion 49 Section 5.05. Adjustments to the Conversion Rate 49 Section 5.06. Voluntary Adjustments 60 59 Section 5.07. Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change 61 60 Section 5.08. Exchange in Lieu of Conversion 62 61 Section 5.09. Effect of Common Stock Change Event 63 62 Article 6. Successors 65 64 Section 6.01. When the Company May Merge, Etc. 65 64 Section 6.02. Successor Entity Substituted 65 64 Section 6.03. Exclusion for Asset Transfers with Wholly Owned Subsidiaries 65 64 Article 7. Defaults and Remedies 66 65 Section 7.01. Events of Default 66 65 Section 7.02. Acceleration 68 66 Section 7.03. Sole Remedy for a Failure to Report 68 67 Section 7.04. Other Remedies 70 68 Section 7.05. Waiver of Past Defaults 70 68 Section 7.06. Control by Majority 70 69 Section 7.07. Limitation on Suits 70 69 Section 7.08. Absolute Right of Holders to Institute Suit for the Enforcement of the Right to Receive Payment and Conversion Consideration 71 69 Section 7.09. Collection Suit by Trustee 71 70 Section 7.10. Trustee May File Proofs of Claim 71 70 Section 7.11. Priorities 72 70 Section 7.12. Undertaking for Costs 72 71 Article 8. Amendments, Supplements and Waivers 73 71 Section 8.01. Without the Consent of Holders 73 71 Section 8.02. With the Consent of Holders 74 72 Section 8.03. Notice of Amendments, Supplements and Waivers 75 73 Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc. 75 73 Section 8.05. Notations and Exchanges 76 74 Section 8.06. Trustee to Execute Supplemental Indentures 76 74 Article 9. Satisfaction and Discharge 76 75 Section 9.01. Termination of Company’s Obligations 76 75 Section 9.02. Repayment to Company 77 75 Section 9.03. Reinstatement 77 76 Article 10. Trustee 77 76 Section 10.01. Duties of the Trustee 77 76 Section 10.02. Rights of the Trustee 79 77 Section 10.03. Individual Rights of the Trustee 80 78 Section 10.04. Trustee’s Disclaimer 80 78 Section 10.05. Notice of Defaults 80 78 Section 10.06. Compensation and Indemnity 81 79 Section 10.07. Replacement of the Trustee 81 80 Section 10.08. Successor Trustee by XxxxxxMerger, Etc. 82 81 Section 10.09. Eligibility; Disqualification 83 81 Article 11. Miscellaneous 83 81 Section 11.01. Notices 83 81 Section 11.02. Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent 85 83 Section 11.03. Statements Required in Officer’s Certificate and Opinion of Counsel 85 83 Section 11.04. Rules by the Trustee, the Registrar, the Paying Agent and the Conversion Agent 85 84 Section 11.05. No Personal Liability of Directors, Officers, Employees and Stockholders 86 84 Section 11.06. Governing Law; Waiver of Jury Trial 86 84 Section 11.07. Submission to Jurisdiction 86 84 Section 11.08. No Adverse Interpretation of Other Agreements 86 84 Section 11.09. Successors 86 85 Section 11.10. Force Majeure 87 85 Section 11.11. U.S.A. PATRIOT Act 87 85 Section 11.12. Calculations 87 85 Section 11.13. Severability 87 85 Section 11.14. Counterparts 87 86 Section 11.15. Table of Contents, Headings, Etc. 88 86 Section 11.16. Withholding Taxes 88 86 Exhibit A: Form of Note A-1 Exhibit B-1: Form of Restricted Note Legend B1-1 Exhibit B-2: Form of Global Note Legend B2-1 Exhibit B-3: Form of Non-Affiliate Resale Legend B3-1 INDENTURE, dated as of April 17October 18, 20232024, between Mirum PharmaceuticalsGuidewire Software, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders (as defined below) of the Company’s 4.001.25% Convertible Senior Notes due 2029 (the “Notes”).
Appears in 1 contract
Samples: Indenture (Guidewire Software, Inc.)
